Biora Therapeutics Valuation
| BIOR Stock | USD 1.67 0.04 2.45% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Biora Therapeutics shows a prevailing Real Value of $14.2 per share. The current price of the firm is $1.67. Our model approximates the value of Biora Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 0.10 %, return on asset of -1.25, and Current Valuation of 44 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biora Therapeutics' valuation include:
Enterprise Value 44 M | Enterprise Value Ebitda (2.03) | Price Sales 8.7825 | Trailing PE 4.6389 | Enterprise Value Revenue 49.3306 |
Undervalued
Today
Please note that Biora Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Biora Therapeutics is based on 3 months time horizon. Increasing Biora Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Biora stock is determined by what a typical buyer is willing to pay for full or partial control of Biora Therapeutics. Since Biora Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biora Stock. However, Biora Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.67 | Real 14.2 | Target 51.87 | Hype 1.05 | Naive 1.85 |
The intrinsic value of Biora Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biora Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biora Therapeutics helps investors to forecast how Biora stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biora Therapeutics more accurately as focusing exclusively on Biora Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biora Therapeutics' intrinsic value based on its ongoing forecasts of Biora Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biora Therapeutics' closest peers.
Biora Therapeutics Cash |
|
Biora Valuation Trend
Biora Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Biora Therapeutics' financial worth over time. Using both Biora Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Biora Therapeutics Total Value Analysis
Biora Therapeutics is currently estimated to have valuation of 44 M with market capitalization of 7.55 M, debt of 47.43 M, and cash on hands of 37.06 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biora Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
44 M | 7.55 M | 47.43 M | 37.06 M |
Biora Therapeutics Investor Information
About 29.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Biora Therapeutics had 1:10 split on the 18th of October 2024. Based on the key indicators related to Biora Therapeutics' liquidity, profitability, solvency, and operating efficiency, Biora Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Biora Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biora Therapeutics has an asset utilization ratio of 0.0128 percent. This connotes that the Company is making $1.28E-4 for each dollar of assets. An increasing asset utilization means that Biora Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Biora Therapeutics Ownership Allocation
Almost 70.51 percent of Biora Therapeutics outstanding shares are held by general public with 0.1 (percent) owned by insiders and only 29.39 % by other corporate entities.Biora Therapeutics Profitability Analysis
The company reported the previous year's revenue of 4 K. Net Loss for the year was (124.11 M) with profit before overhead, payroll, taxes, and interest of 1.25 M.About Biora Therapeutics Valuation
The stock valuation mechanism determines Biora Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Biora Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biora Therapeutics. We calculate exposure to Biora Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biora Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -551 K | -523.5 K | |
| Pretax Profit Margin | (185.70) | (176.41) | |
| Operating Profit Margin | -16.8 K | -15.9 K | |
| Net Loss | -31 K | -29.5 K | |
| Gross Profit Margin | (137.75) | (130.86) |
Biora Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Biora Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 15.8 M |
Biora Therapeutics Current Valuation Indicators
Biora Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Biora Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biora Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biora Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biora Therapeutics' worth.Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.